Medicinal Products

Dáil Éireann Debate, Thursday - 26 February 2026

• Debates
• Find a debate
  • Dáil debates
  • Seanad debates
  • Committee debates
• Find a vote
  • Dáil votes
  • Seanad votes
  • Committee votes
• Parliamentary questions
  • Written questions
  • Oral questions
• Search tips
• Utterances having an adverse effect

Thursday, 26 February 2026

Questions (513)

Ken O'Flynn

Question:

513. Deputy Ken O'Flynn asked the Minister for Health whether one-way or probabilistic sensitivity analyses were conducted as part of the pharmacoeconomic evaluations of tirzepatide and semaglutide; and if so, the key variables identified as having the greatest impact on cost-effectiveness outcomes. [15814/26]

Written answers

Minister for Health

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

• Previous Answer
• Next Answer